Johns Hopkins University and Bloomberg Philanthropies today announced the launch of a $150 million effort to directly address historic underrepresentation in science, technology, engineering, and math fields, and to prepare a new, more diverse generation of researchers and scholars to assume leading roles in tackling some of the world’s greatest challenges.
ROCKVILLE, Md., May 12, 2021 /PRNewswire/ — Emmes (the “Company”), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation and a portfolio company of Behrman Capital, today announced that it has acquired Orphan Reach, a CRO specialized in clinical research related to rare diseases. Financial terms of the transaction were not disclosed.
Set on the historic Walter Reed Army Medical Center, the Children’s National Research & Innovation Campus will be a one-of-kind innovation hub. The nearly 12-acre campus will house leading entrepreneurs, thinkers, innovators and experts aiming to improve the health and well-being of patients around the world. Johnson & Johnson Innovation – JLABS @ Washington, DC will occupy a 32,000—square foot facility open to biotech, medical device, consumer and health technology start-ups aiming to develop new medicines, medical devices, precision diagnostics and health tech applications. Additionally, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, JLABS @ Washington, DC will be the hub for BLUE KNIGHT. Blue Knight is a collaboration dedicated to and aimed at anticipating health security threats, activating the global innovation community, and amplifying technological advancements to prepare for and respond to our rapidly evolving global health environment. We look forward to the opening of JLABS @ Washington, DC in collaboration with our partners at Children’s National Hospital and BARDA to support innovation for patients.
GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor. Proceeds of this financing will be used to accelerate clinical development of PhageBank™ phage therapies, as well as for general corporate purposes.
By 2022, Frederick County will see an estimated 1,500 new jobs after diagnostics solutions company Ellume moves in.
The Australian-based company, which makes at-home COVID-19 tests, is set to open its first U.S. manufacturing facility in Frederick, county officials announced Monday.
The 180,000-square-foot facility in the Progress Labs Corporate Park off Md. 85 will be home to the plant.
Ellume, an Australian company specializing in diagnostics solutions for infectious diseases, is set to open its first U.S. manufacturing facility in Frederick, county officials announced Monday.
The 180,000-square-foot facility in the Progress Labs Corporate Park off Md. 85 will serve as a manufacturing plant, where Ellume will make at-home COVID-19 tests and bring an estimated 1,500 jobs to Frederick County by 2022.
“This is great news for Frederick County,” Frederick County Executive Jan Gardner said in a news release. “Ellume is on the cutting edge, making products that will help the world to overcome this health pandemic. We are excited to welcome Ellume to our thriving life science and biopharma family.”
Image: Courtesy photo via ellumehealth.com
Maryland’s biohealth boom continues, with Australian bio company Ellume announcing its entrance in the United States. Ellume, a Queensland digital diagnostics company, recently signed a $231.8 million agreement with the federal government to accelerate domestic production of its COVID-19 home tests. The company will establish a manufacturing facility in Maryland, its first in the United States, to accommodate the demand for its products targeting infectious diseases.
ROCKVILLE, MARYLAND, May 10, 2021 – BioHealth Innovation Inc. (BHI) announces the addition of Dr. Natsumi Takahashi-Vitiello, PhD in the role of Analyst. In her new position, Dr. Takahashi-Vitiello will assist the Entrepreneurs-in-Residence (EIR) Program at BHI in the evaluation of early-stage technologies, strategic planning for start-up companies, and identification/developmental strategies of new venture opportunities.
“I am pleased to welcome Dr. Natsumi Takahashi-Vitiello to the BHI family,” said Richard Bendis, BHI President, and CEO. “Her biohealth business experience and scientific background will support the BHI clients in their commercialization and fund-raising activities.”
Rich Bendis welcomes Dr. Anne Khademian, Executive Director, The Universities at Shady Grove, on BioTalk to discuss Higher Ed in Montgomery County, their Biomedical Sciences and Engineering (BSE) facility, and Strategic Partnerships.
Listen now on Apple https://apple.co/3xYZG9P , Google https://bit.ly/3eyQ6mm, Spotify https://spoti.fi/3o4vztl, and TuneIn https://bit.ly/2SHbI7N.
Dr. Anne Khademian was named to serve as the Universities at Shady Grove’s third executive director in October 2020, following a nationwide search and her appointment to the post by Dr. Jay Perman, Chancellor of the University System of Maryland. As executive director of USG – a regional higher education center of USM in Montgomery County, with programs from nine universities on one campus – Dr. Khademian also holds the title of Associate Vice Chancellor for Academic Affairs for USM.
Aziyo Biologics Inc. is executing growth plans it established ahead of its initial public offering last fall — and starting to see results.
The regenerative medicine firm, which started trading on the Nasdaq in October, saw a first-quarter revenue increase year over year “despite some ongoing Covid-related headwinds,” President and CEO Ron Lloyd said in a statement this week.
